new-molecular-drivers-in-nsclc-the-role-of-met
MET Inhibition in Non-Small Cell Lung Cancer - European Medical Journal
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients - Annals of Oncology
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exo | LCTT
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
DISSECT platform with multi-omics data and various analytic tools - CNGBdb
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
FISH analysis of de novo MET amplification in advanced NSCLC and... | Download Scientific Diagram
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Incidence and PD-L1 Expression of MET 14 Skipping in Chinese Populatio | OTT
Early Alectinib Resistance From MET Amplification in ALK Rearranged NSCLC: Response to Crizotinib with Re-response to Alectinib and Crizotinib - Clinical Lung Cancer
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis. - Abstract - Europe PMC
Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib - Lung Cancer
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
new-molecular-drivers-in-nsclc-the-role-of-met
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling | Science
Targeting the MET Pathway for Lung Cancer Treatments, Biomarkers
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer | Clinical Cancer Research
Chidamide increases the sensitivity of non-small cell lung cancer to crizotinib by decreasing c-MET mRNA methylation | bioRxiv
EGFR pathway in NSCLC. Mutations, amplification or overexpression of... | Download Scientific Diagram
